Ulcerative colitis (UC) is a relapsing-remitting inflammatory bowel disease that requires numerous costly invasive investigations which lead to physical and psychological patient discomfort. We need a non-invasive technological approach that would significantly improve its diagnosis. Surface-enhanced Raman scattering (SERS) is a growing technique that can provide a molecular diagnostic fingerprint in just a few minutes, without the need for prior sample preparation. The aim of this pilot in vivo study was to prove that multivariate analysis of SER spectra collected on plasma samples could be employed for non-invasive diagnosis of UC. Plasma samples were collected from healthy subjects (n = 35) and patients with UC (n = 28). SERS spectra were acquired using a 785-nm excitation laser line and a solid plasmonic substrate developed in our laboratory using an original procedure described in the literature. The classification accuracy yielded by SERS was assessed by principal component analysis-linear discriminant analysis (PCA-LDA) and partial least squares discriminant analysis (PLS-DA). PCA-LDA differentiated UC samples from those of healthy subjects with a sensitivity of 86%, a specificity of 92%, and an accuracy of 89%, the AUC being 0.96. The PLS-DA analysis resulted in a sensitivity of 89%, a specificity of 94%, an accuracy of 92%, and an AUC value of 0.92. Several spectral bands were associated with UC: 376-420, 440-513, 686-715, 919-939, 1035-1062, 1083-1093, 1120-1132, 1148-1156, 1191-1211, 1234-1262, 1275-1294, 1382-1405, 1511-1526, and 1693-1702 cm-1. Changes in plasma levels of amino acids, proteins, lipids, and other compounds were noted using SERS in patients with UC. Multivariate analysis of SER spectra collected on a solid plasmonic substrate represents a promising alternative to diagnosing UC, as it is non-invasive, easy to use, and fast.
Keywords: Inflammatory bowel disease; SERS; Solid plasmonic substrate; Surface-enhanced Raman spectroscopy; Ulcerative colitis.